[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100431544":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":28,"responsibleParty":49,"collaborators":18,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":18,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":18,"enrollmentInfo":60,"targetDuration":18,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":18,"overallStatus":31,"whyStopped":18,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"RedDress Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ActiGraft","EXPERIMENTAL","Whole blood clot (WBC) gel",[13],"Device: ActiGraft",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"DEVICE",[9],null,[20],{"name":21,"affiliation":5,"role":22},"Sharon Sirota","STUDY_DIRECTOR",[24],{"name":21,"role":25,"phone":26,"phoneExt":18,"email":27},"CONTACT","+972545800765","sharon@reddress.co.il",[29],{"facility":30,"status":31,"city":32,"state":18,"zip":18,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Meir Medical Center","RECRUITING","Kfar Saba","Israel","IL",{"type":36,"coordinates":37},"Point",[38,39],34.90694,32.175,{"lat":39,"lon":38},[42,46],{"name":43,"role":25,"phone":44,"phoneExt":18,"email":45},"Asia Kaizler","+972506943426","asia.kaizler@clalit.org.il",{"name":47,"role":48,"phone":18,"phoneExt":18,"email":18},"Zvi Klein, Dr. Med.","PRINCIPAL_INVESTIGATOR",{"type":50,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100431544","efficacy-evaluation-of-actigraft-in-secondary-closure-of-abdominal-surgical-wound-dehiscence-100431544",false,"NCT04899466","Efficacy Evaluation of ActiGraft in Secondary Closure of Abdominal Surgical Wound Dehiscence","A Prospective Study Evaluating the Efficacy of ActiGraft in Secondary Closure of Abdominal Surgical Wound Dehiscence","Inclusion Criteria:\n\n* Age \\>18 years\n* Women that had a laparotomy no more than 3 weeks before accrual.\n* Surgical wound dehiscence that requires a secondary closure.\n* Time from wound dehiscence \\>24 hours and \\\u003C6 days.\n* The open wound includes epidermis, dermis and sub cutaneous fat.\n* The patient can sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with necrotizing fasciitis\n* Patients with fascial dehiscence\n* Cannot withdraw blood in the required amount (up to 18 mL per week).\n* Known coagulation problems, abnormal thrombocytes level or if heparin is given intravenously. Subjects who are taking oral anti-coagulants or anti-agreganrts will not be excluded.\n* Pregnancy\n* Subject is currently receiving (i.e., within the past 30 days) or scheduled to receive systemic steroids (Prednisone- more than 10mg\u002Fd or equivalent).","FEMALE","18 Years",{"count":61,"type":62},20,"ESTIMATED","INTERVENTIONAL",[65],"NA","This is a prospective, single arm study, consisting of 20 women with abdominal surgical wound dehiscence that requires secondary closure. The participants will receive a weekly application of ActiGraft for 4 weeks, or until complete healing of the wound (the earlier of the two).\n\nAn historic matched-control group of 20 patients will be compared retrospectively",[68],"Dehiscence Wound","2024-11-13",{"date":71,"type":72},"2024-11-15","ACTUAL",{"date":74,"type":72},"2021-08-01",{"date":76,"type":62},"2026-08-01",{"name":5,"class":6},1]